CellOPTIQ® Services

CiPA Studies

Clyde Biosciences is an official member of the CiPA consortium. Clyde’s status as a Core Group member allows us to contribute towards the development of the next generation of assays reducing false positive and false negative results. Clyde is fully committed to the goals of improving patient safety and reducing animal usage.

CellOPTIQ® – Power of 3

Uniquely measuring voltage, calcium and contractility in the same cells, the Power of 3 sets Clyde Biosciences apart. One experiment gives our clients the principal measurements they need to assess the potential for cardiotoxicity in their compounds. This approach saves time, money and unnecessary in vivo experiments.


See more services

Core Services


Heart cell contractility is a sensitive indicator of toxic or therapeutic effects of drugs. CellOPTIQ® provides visual measurements of cells at high frequency providing a wealth of data for the assessment of potential contractility effects.


Current assays may not have the sensitivity to detect changes in action potential upstroke.
CellOPTIQ® from Clyde Biosciences is the only assay able to capture data fast enough to measure changes in upstroke directly.


Intracellular calcium transient measurements are critical for the understanding of cardiac function. Clyde’s CellOPTIQ® is a powerful tool, offering more accuracy and higher throughput than other assays.

View in Detail

Other Services

Ion Channel Screening

Clyde is able to provide our clients with access to the highest quality ion channel screening technology

Custom R&D

Many of Clyde Biosciences’ clients have specific research needs which cannot be met using older technologies. We work with our clients to craft protocols to meet their research needs. Clyde’s CellOPTIQ™ system is a powerful and flexible tool unlike anything else available on the market.

Stem Cell Characterisation

Clyde Biosciences works with the leading manufacturers of iPS-CMs to provide a broad dataset of parameters, enabling companies to understand the performance of their cells in the context of drug testing.

In Silico Modelling

In Silico screening will become a cornerstone of cardiotox testing in drug development. Clyde Biosciences’ in silico service provides confidence about ion channel measurement of drug activity.

View in Detail

Expert Team


Discover Clyde Biosciences

Clyde Biosciences is a leading company in the field of cardiac safety testing.
Building on more than 100 years of combined experience, our team is ready to help you meet your preclinical cardiotox testing goals.

Clyde’s unique Power of 3 assay service provides our clients the confidence they need to proceed to in vivo compound testing.

Latest news

Groundbreaking Research Into Kinases Using CellOPTIQ From Clyde Biosciences

Recent Publication Highlights Flexibility and Power of Clyde’s CellOPTIQ® Assay Highlights Collaboration with AZ on kinase inhibitor induced cardiotoxicity Understanding E-C coupling is essential in kinase research CellOPTIQ® is the only single mechanistic screen providing insight into E-C coupling mechanism Observing the interplay between voltage, calcium transient and contractility is vital and is only available […]

Clyde Biosciences

New Website

WELCOME TO OUR NEW WEBSITE Clyde Biosciences is delighted to launch our new website. Have a good look around and please get in touch with feedback or inquiries.

Clyde Biosciences

Clyde Biosciences Autumn Business Update

Clyde Biosciences Autumn Business Update Highlights CiPA 28 study finished and data submitted weeks ahead of schedule New CellOPTIQ®-X contractility assay launched New Heart Failure model launched Clyde Biosciences today announces progress in its autumn business update. The company reports that in the last three months it has completed work on a number of important […]

See all our news